By modulating immune health and enhancing muscle function, we become one step closer towards a healthier lifespan. 

Immunis is a private biotechnology company targeting age-driven diseases and immune dysfunction. Our team developed a novel method to isolate clinical-grade, secreted cellular factors with immune modulating capabilities that can benefit immune system health and development. Our investigational IMM01-STEM therapy contains all-natural bioactive molecules published in aged mouse models to improve muscle mass and strength, enhance immune cell recruitment, increase lean mass, reduce fat mass, and increase physical activity. Immunis completed a Phase 1/2a clinical trial testing the safety, tolerability, and efficacy of IMM01-STEM in sarcopenic individuals with knee osteoarthritis and is conducting a Phase 2 placebo-controlled study in adults (aged 50+) with sarcopenic obesity.